Prevention & Lipids
Statin efficacy, safety, and optimal intensity
Also called statins, HMG-CoA reductase inhibitors
Sources: 5 landmark trials · 12 new papers · 5 key papers · updated Oct 20, 2026
What 7 experts said about this trial's result
Expert labels are toward STAREE's result, from named public quotes (n=7). As of Nov 6, 2026.
Unverified · drafted by AI from the sources cited below
Statin therapy utilizes compounds that inhibit HYDROXYMETHYLGLUTARYL COA REDUCTASES.1 They have been shown to directly lower CHOLESTEROL synthesis.1
Among patients receiving contemporary statins, high-sensitivity C-reactive protein and low-density lipoprotein cholesterol serve as biomarkers of residual risk for major adverse cardiovascular events.1 Additionally, elevated apolipoprotein B and non-high-density lipoprotein cholesterol are associated with an increased risk of all-cause mortality and myocardial infarction in statin-treated populations.2 In a cohort of 13,015 statin-treated patients followed for a median of 8 years, discordant apolipoprotein B yielded a hazard ratio of 1.21.2
In a retrospective cohort study of 601 934 patients with established atherosclerotic cardiovascular disease, 22.5% were on a high-intensity statin, 27.6% were on low- or moderate-intensity statin, and 49.9% were not on any statin.1 For secondary prevention in patients already taking guideline-directed medical care including statins, low-dose colchicine at 0.5 mg/d orally lowers major adverse cardiovascular events by 31% in stable atherosclerosis and 23% after recent myocardial infarction.2 During pregnancy, first-trimester exposure to statins was associated with major birth defects in 7.4% of 135 infants compared to 2.4% of 501 unexposed infants, resulting in an adjusted relative risk of 2.16.3 Furthermore, the cumulative incidence of spontaneous abortion was 26.8% in the statin-exposed group versus 15.0% in the comparison cohort.3
Ongoing reviews aim to evaluate the benefits and harms of statins in the secondary prevention of recurrent venous thromboembolic disease among adults aged over 70 years.1 Evidence regarding statin therapy and 28-day survival in non-acute myocardial infarction cardiogenic shock remains limited.2
Genome-Wide and Exome-Wide Significant Genetic Variants Influencing Rosuvastatin Therapy: A Scoping Review
Journal of Cardiovascular Pharmacology and Therapeutics — Dermota T — Nov 2026
Primary results of 5 trials behind the evidence on statin therapy, as each trial’s own publication reports them.
Left of the line at 1 favours the intervention; square size tracks trial size.Favours the interventionNo significant differenceFavours the comparator
simvastatin-ezetimibe vs simvastatin monotherapy · 18,144 patients · N Engl J Med 2015
In patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days
Primary outcome: a composite of cardiovascular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary revascularization (≥30 days after randomization), or nonfatal stroke
Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials
The Lancet — Ridker P
734 citations · 2023 · among the most cited on Statin therapy
Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients
Journal of the American College of Cardiology — Johannesen C
380 citations · 2021 · among the most cited on Statin therapy
Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial
The Lancet — Kim B
351 citations · 2022 · among the most cited on Statin therapy
Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease
Journal of the American College of Cardiology — Nelson K
212 citations · 2023 · among the most cited on Statin therapy
A clinical question appears here only when its condition matches this topic, an outcome and a comparator were extracted from the studies, at least two studies and a patient count are on file, and the certainty is low or higher.
Supports benefit, no benefit shown, and mixed describe the direction of the measured effect. No benefit shown means the evidence does not support a benefit. It is not a finding of harm. Too little evidence means the question did not clear that bar.
Study count, RCT count, and patient count are separate. The patient total adds only studies that are linked into a study family and whose sample size is not flagged as implausible. A reversal is listed only when at least one randomized trial sits on each side of the change.
The overview is drafted from the guideline recommendations, trials, papers, and questions on this page, and every sentence has to cite one of them. It stays unverified until an NPI-verified clinician or a Synapse admin approves it. Approving records that person's name.
Current Atherosclerosis Reports — Jabbar A — Oct 2026
HR 0.936 (0.89–0.99)
rosuvastatin vs placebo · 17,802 patients · N Engl J Med 2008
In apparently healthy men and women with low-density lipoprotein (LDL) cholesterol levels of less than 130 mg per deciliter (3.4 mmol per liter) and high-sensitivity C-reactive protein levels of 2.0 mg per liter or higher
Primary outcome: myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from cardiovascular causes
HR 0.56 (0.46–0.69)
atorvastatin vs placebo · 4,731 patients · N Engl J Med 2006
In patients who had had a stroke or TIA within one to six months before study entry
Primary outcome: a first nonfatal or fatal stroke
HR 0.84 (0.71–0.99)
80 mg of atorvastatin vs 10 mg of atorvastatin · 10,001 patients · N Engl J Med 2005
In patients with clinically evident CHD and LDL cholesterol levels of less than 130 mg per deciliter (3.4 mmol per liter)
Primary outcome: the occurrence of a first major cardiovascular event, defined as death from CHD, nonfatal non-procedure-related myocardial infarction, resuscitation after cardiac arrest, or fatal or nonfatal stroke
HR 0.78 (0.69–0.89)
atorvastatin vs placebo · 10,305 patients · Lancet 2003
In hypertensive patients (aged 40-79 years with at least three other cardiovascular risk factors)
Primary outcome: non-fatal myocardial infarction and fatal CHD
HR 0.64 (0.50–0.83)
Results are quoted from each trial’s primary publication abstract (PubMed); the trial name links to the paper. Ratios below 1 favour the intervention.